Imugene Ltd Cash Flow Conversion Efficiency
Imugene Ltd cash flow conversion efficiency. Based on the latest financial reports, Imugene Ltd (IMU) has a cash flow conversion efficiency ratio of -0.620x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-25.97 Million ≈ $-18.38 Million USD) by net assets (AU$41.87 Million ≈ $29.62 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Imugene Ltd (1993–2025)
Cash flow conversion efficiency of Imugene Ltd from 1993 to 2025. This chart illustrates how Imugene Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Imugene Ltd stock price for real-time trading data and today's change.
Imugene Ltd Cash Flow Conversion Ratio Explained
Imugene Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Imugene Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Imugene Ltd ranked by their cash flow conversion efficiency. Also see Imugene Ltd (IMU) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
NPK Co.Ltd
KQ:048830
|
0.058x |
|
Active Biotech AB
ST:ACTI
|
-0.242x |
|
Netlinkz Ltd
AU:NET
|
0.084x |
|
Kingfish Company Nv
OL:KING
|
-0.078x |
|
HANHUA FNCL HLDG CO.H YC1
F:5HF
|
N/A |
|
Huize Holding Ltd
NASDAQ:HUIZ
|
-0.197x |
|
Bodhi Tree Multimedia Limited
NSE:BTML
|
0.001x |
|
Goodyear Lastikleri TAS
IS:GOODY
|
0.150x |
Annual Cash Flow Conversion Efficiency for Imugene Ltd (1993–2025)
The table below shows the annual cash flow conversion efficiency of Imugene Ltd from 1993 to 2025. Review Imugene Ltd free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$45.03 Million ≈ $31.86 Million |
AU$-75.57 Million ≈ $-53.47 Million |
-1.678x | -95.07% |
| 2024-06-30 | AU$118.25 Million ≈ $83.67 Million |
AU$-101.73 Million ≈ $-71.98 Million |
-0.860x | -447.78% |
| 2023-06-30 | AU$189.63 Million ≈ $134.17 Million |
AU$-29.78 Million ≈ $-21.07 Million |
-0.157x | +28.98% |
| 2022-06-30 | AU$138.70 Million ≈ $98.14 Million |
AU$-30.67 Million ≈ $-21.70 Million |
-0.221x | -9.50% |
| 2021-06-30 | AU$65.02 Million ≈ $46.00 Million |
AU$-13.13 Million ≈ $-9.29 Million |
-0.202x | -19.19% |
| 2020-06-30 | AU$59.81 Million ≈ $42.32 Million |
AU$-10.13 Million ≈ $-7.17 Million |
-0.169x | +41.54% |
| 2019-06-30 | AU$27.29 Million ≈ $19.31 Million |
AU$-7.91 Million ≈ $-5.60 Million |
-0.290x | +0.52% |
| 2018-06-30 | AU$15.48 Million ≈ $10.95 Million |
AU$-4.51 Million ≈ $-3.19 Million |
-0.291x | -24.18% |
| 2017-06-30 | AU$11.39 Million ≈ $8.06 Million |
AU$-2.67 Million ≈ $-1.89 Million |
-0.235x | +39.56% |
| 2016-06-30 | AU$7.86 Million ≈ $5.56 Million |
AU$-3.05 Million ≈ $-2.16 Million |
-0.388x | -46.86% |
| 2015-06-30 | AU$7.73 Million ≈ $5.47 Million |
AU$-2.04 Million ≈ $-1.45 Million |
-0.264x | -55.52% |
| 2014-06-30 | AU$6.73 Million ≈ $4.76 Million |
AU$-1.14 Million ≈ $-809.52K |
-0.170x | +76.58% |
| 2013-06-30 | AU$1.89 Million ≈ $1.33 Million |
AU$-1.37 Million ≈ $-968.40K |
-0.726x | +19.38% |
| 2012-06-30 | AU$1.07 Million ≈ $759.51K |
AU$-965.92K ≈ $-683.45K |
-0.900x | -447.17% |
| 2011-06-30 | AU$4.21 Million ≈ $2.98 Million |
AU$1.09 Million ≈ $771.53K |
0.259x | +156.39% |
| 2010-06-30 | AU$3.79 Million ≈ $2.68 Million |
AU$-1.74 Million ≈ $-1.23 Million |
-0.460x | -377.67% |
| 2009-06-30 | AU$5.33 Million ≈ $3.77 Million |
AU$881.77K ≈ $623.91K |
0.166x | +160.74% |
| 2008-06-30 | AU$4.67 Million ≈ $3.30 Million |
AU$-1.27 Million ≈ $-900.66K |
-0.273x | +24.77% |
| 2007-06-30 | AU$4.70 Million ≈ $3.33 Million |
AU$-1.70 Million ≈ $-1.20 Million |
-0.362x | -27.73% |
| 2006-06-30 | AU$6.46 Million ≈ $4.57 Million |
AU$-1.83 Million ≈ $-1.30 Million |
-0.284x | -50.67% |
| 2005-06-30 | AU$8.65 Million ≈ $6.12 Million |
AU$-1.63 Million ≈ $-1.15 Million |
-0.188x | +32.68% |
| 2004-06-30 | AU$5.43 Million ≈ $3.84 Million |
AU$-1.52 Million ≈ $-1.07 Million |
-0.280x | +71.84% |
| 2002-06-30 | AU$792.83K ≈ $560.98K |
AU$-787.36K ≈ $-557.11K |
-0.993x | -108.81% |
| 2001-06-30 | AU$-226.54K ≈ $-160.29K |
AU$-2.55 Million ≈ $-1.81 Million |
11.266x | +892.20% |
| 2000-06-30 | AU$2.78 Million ≈ $1.97 Million |
AU$-3.95 Million ≈ $-2.80 Million |
-1.422x | -147.09% |
| 1999-06-30 | AU$6.00 Million ≈ $4.24 Million |
AU$-3.45 Million ≈ $-2.44 Million |
-0.576x | -99.40% |
| 1997-06-30 | AU$7.45 Million ≈ $5.27 Million |
AU$-2.15 Million ≈ $-1.52 Million |
-0.289x | -16.06% |
| 1996-06-30 | AU$8.12 Million ≈ $5.75 Million |
AU$-2.02 Million ≈ $-1.43 Million |
-0.249x | -58.27% |
| 1995-06-30 | AU$10.62 Million ≈ $7.52 Million |
AU$-1.67 Million ≈ $-1.18 Million |
-0.157x | -20.81% |
| 1994-06-30 | AU$11.19 Million ≈ $7.91 Million |
AU$-1.46 Million ≈ $-1.03 Million |
-0.130x | -235.76% |
| 1993-06-30 | AU$5.11 Million ≈ $3.62 Million |
AU$-198.00K ≈ $-140.10K |
-0.039x | -- |
About Imugene Ltd
Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA,… Read more